Vesicant chemotherapy extravasation antidotes and treatments.
Oncology nurses and pharmacists often are given the responsibility of developing or updating institutional policies to manage vesicant chemotherapy extravasations. Antidote and treatment recommendations of vesicant chemotherapy manufacturers, antidotes and treatments approved by the U.S. Food and Drug Administration (FDA), and guidelines and recommendations made by professional oncology organizations are useful resources in this process. This article describes manufacturers' recommendations, lists antidotes and treatments approved by the FDA, and reviews published guidelines and recommendations. Available antidote and treatment formulations and their preparation and administration also are discussed.
Schulmeister
Lisa
L
Oncology Nursing Consultant, River Ridge, LA, USA. lisaschulmeister@hotmail.com
D000931:Antidotes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000188:drug therapy* / Q000451:nursing; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D009859:Oncology Nursing; D012307:Risk Factors
D000931:Antidotes; D000970:Antineoplastic Agents